We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.36% | 27.60 | 27.50 | 28.70 | 28.60 | 27.40 | 28.60 | 289,974 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 52.88 | 125.11M |
TIDMEKF
RNS Number : 9264Z
EKF Diagnostics Holdings PLC
20 September 2022
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Dividend Timetable
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.
The dividend timetable dates are detailed below:
Ex-dividend 3 November 2022 date: Record date: 4 November 2022 Payment date: 1 December 2022 EKF Diagnostics Holdings plc www.ekfdiagnostics.com Mike Salter, CEO / Marc Davies, CFO Tel: +44 (0)29 2071 0570 Singer Capital Markets (Nominated Adviser Tel: +44 (0)20 7496 3000 & Joint Broker) Aubrey Powell / George Tzimas / Oliver Platts Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000 Gary Clarence / Daniel Adams / Ben Farrow Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin Life Sciences Enzyme fermentation, Custom products and Bulk fermentation Contract Manufacturing Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits Laboratory Testing Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCGPUCPBUPPGQB
(END) Dow Jones Newswires
September 20, 2022 02:01 ET (06:01 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions